The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Cognitive enhancement as a pharmacotherapy target for stimulant addiction
Open accessAbstract
Background No medications have been proven to be effective for cocaine and methamphetamine addiction. Attenuation of drug reward has been the main strategy for medications development, but this approach has not led to effective treatments. Thus, there is a need to identify novel treatment targets in addition to the brain reward system. Aim To propose a novel treatment strategy for stimulant addiction that will focus on medications enhancing cognitive function and attenuating drug reward. Methods Pre‐clinical and clinical literature on potential use of cognitive enhancers for stimulant addiction pharmacotherapy was reviewed. Results and conclusions Cocaine and methamphetamine users show significant cognitive impairments, especially in attention, working memory and response inhibition functions. The cognitive impairments seem to be predictive of poor treatment retention and outcome. Medications targeting acetylcholine and norepinephrine are particularly well suited for enhancing cognitive function in stimulant users. Many cholinergic and noradrenergic medications are on the market and have a good safety profile and low abuse potential. These include galantamine, donepezil and rivastigmine (cholinesterase inhibitors), varenicline (partial nicotine agonist), guanfacine (alpha 2‐adrenergic agonist) and atomoxetine (norepinephrine transporter inhibitor). Future clinical studies designed optimally to measure cognitive function as well as drug use behavior would be needed to test the efficacy of these cognitive enhancers for stimulant addiction.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cholinesterase inhibitors for Alzheimer's disease
Birks, J. S. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005593 · Cited by 1,906
Impulsivity as a determinant and consequence of drug use: a review of underlying processes
de Wit, H. (2009) · Addiction Biology · doi:10.1111/j.1369-1600.2008.00129.x · Cited by 1,415
Ressler, K. J., Rothbaum, B. O., Tannenbaum, L., Anderson, P., Graap, K., Zimand, E., Hodges, L., & Davis, M. (2004) · Archives of General Psychiatry · doi:10.1001/archpsyc.61.11.1136 · Cited by 1,063
Varenicline: An α4β2 Nicotinic Receptor Partial Agonist for Smoking Cessation
Coe, J. W., Brooks, P. R., Vetelino, M. G., Wirtz, M. C., Arnold, E. P., Huang, J., Sands, S. B., Davis, T. I., Lebel, L. A., Fox, C. B., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm050069n · Cited by 930
Left inferior frontal gyrus is critical for response inhibition
Swick, D., Ashley, V., & Turken, A. U. (2008) · BMC Neuroscience · doi:10.1186/1471-2202-9-102 · Cited by 745
Hester, R., & Garavan, H. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.3321-04.2004 · Cited by 657
Kuczenski, R., & Segal, D. S. (1997) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1997.68052032.x · Cited by 623 · cited 1×
“In contrast, amphetamines increase both DA and NE levels in the nucleus accumbens and in the PFC [97].”
BackgroundNeurochemical Modulation of Response Inhibition and Probabilistic Learning in Humans
Chamberlain, S. R., Müller, U., Blackwell, A. D., Clark, L., Robbins, T. W., & Sahakian, B. J. (2006) · Science · doi:10.1126/science.1121218 · Cited by 573
Impaired inhibitory control of behavior in chronic cocaine users
Fillmore, M. T., & Rush, C. R. (2002) · Drug and Alcohol Dependence · doi:10.1016/s0376-8716(01)00206-x · Cited by 519
Neurobehavioral mechanisms of impulsivity: fronto-striatal systems and functional neurochemistry
Dalley, J. W., Mar, A. C., Economidou, D., & Robbins, T. W. (2008) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2007.12.021 · Cited by 467 · cited 1×
“Increasing evidence from pre-clinical and clinical studies indicate that NE is critical in many PFC cognitive functions, including sustained attention, working memory and response inhibition [86,87].”
Background
Cited by
Bickel, W. K., Jarmolowicz, D. P., Mueller, E. T., Koffarnus, M. N., & Gatchalian, K. M. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.02.004 · Cited by 604
Resting state functional connectivity in addiction: Lessons learned and a road ahead
Sutherland, M. T., McHugh, M. J., Pariyadath, V., & Stein, E. A. (2012) · NeuroImage · doi:10.1016/j.neuroimage.2012.01.117 · Cited by 494
Cognitive enhancement as a treatment for drug addictions
Sofuoglu, M., DeVito, E. E., Waters, A. J., & Carroll, K. M. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.06.021 · Cited by 298
Self-citationBolea-Alamañac, B., Nutt, D. J., Adamou, M., Asherson, P., Bazire, S., Coghill, D., Heal, D., Müller, U., Nash, J., Santosh, P., et al. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881113519509 · Cited by 287
Cognitive function during nicotine withdrawal: Implications for nicotine dependence treatment
Ashare, R. L., Falcone, M., & Lerman, C. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.04.034 · Cited by 170
Metadata
- Authors
- Sofuoglu, M.
- Venue
- Addiction
- Publisher
- Wiley
- Published
- 2009-12-14
- Volume
- 105
- Issue
- 1
- Pages
- 38-48
- ISSN
- 0965-2140 (ISSN-L)
- 1360-0443
- OpenAlex
- W2141405812
- Cited by
- 161
- References
- 31
- FWCI
- 11.31
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cognitive enhancement as a pharmacotherapy target for stimulant addiction. https://app.cochat.ai/papers/10.1111/j.1360-0443.2009.02791.x
- The paper
- Sofuoglu, M. (2010). Cognitive enhancement as a pharmacotherapy target for stimulant addiction. Addiction. https://doi.org/10.1111/j.1360-0443.2009.02791.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.